COVID-19

When SARS-CoV-2 emerged, ISARIC partners leveraged more than a decade of experience in acute respiratory outbreak research to assemble a comprehensive response to the global pandemic.

Existing protocols, established data systems and a prepared global network enabled us to collaborate quickly with hundreds of research ‘sites’ around the globe and generate evidence that contributed to policymaking, clinical trial designs and drug development to reduce the impact of the pandemic.

Working with hundreds of partners around the world, we assembled the world’s largest international collection of accessible data on individuals hospitalized with COVID-19. This dataset continues to help researchers and public health organisations around the world.

Characterising Disease

Clinical Characterisation Protocol

It is a standardised protocol that enables data and biological samples to be collected rapidly in a globally-harmonised manner for any severe or potentially severe acute infection of public health interest. The Clinical Characterisation Protocol (CCP) can be used for the rapid, coordinated clinical investigation of confirmed cases of COVID-19.

Optional CRF Modules

Modules to be used in addition to the Core or RAPID COVID-19 CRFs

MIS-C in children and adolescents

Stand alone CRF for children and adolescents.

Long COVID protocol

Follow-up clinical data collection

Long COVID paediatric

Paediatric protocol and survey for the follow-up of COVID-19 patients

Developing methodologies

COVID-19 Rapid Evidence Reviews Group (CORRE)

High quality rapid evidence synthesis for use in COVID-19 research.

Improving Treatment

Recovery (TBD) Trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit

Removing barriers

In response to the COVID-19 outbreak in Brazil, the ISARIC Hub in Brazil led a community engagement campaign with residents of one of Rio de Janeiro’s favela communities to increase COVID-19 acceptance and uptake. The Regional hub lead for South America, Dr Fernando Bozza partnered with a local NGO, Redes da Maré to carry out this campaign. The campaign was carried out in Maré, a territory consisting of 16 favelas and over 140,000 people. The learnings from engaging this community have been consolidated and published on our community engagement pages.

COVID-19 Research Partner Sites

Publications

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Learn more

Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study

Adults and children can develop post-Covid-19 condition (PCC) (also referred to as Long Covid). However, existing evidence is scarce, partly due to a lack of a standardised case definition, short follow up duration, and heterogenous study designs, resulting in wide variation of reported outcomes. The primary aim of this study was to characterise risk factors for PCC and longitudinal rates of recovery in a cohort of children and young people using a standardised protocol. Learn more

Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients

Learn more

Rolling out COVID-19 antigen rapid diagnostic tests: the time is now

Learn more

Scaling up COVID-19 rapid antigen tests: promises and challenges

Learn more

Modeling the relative influence of socio-demographic variables on post-acute COVID-19 quality of life: an application to settings in Europe, Asia, Africa & South America – Preprint

Learn more

Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19

Endocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies. Learn more

Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study

Learn more

Variability in clinical assessment of clade IIb mpox lesions

Learn more

Evaluation of pragmatic oxygenation measurement as a proxy for COVID-19 severity

Learn more

Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol

Learn more

Neurological manifestation and outcome for patients admitted to hospital with COVID-19: Results from the ISARIC prospective multinational observational study

Learn more

Characteristics and outcomes of an international cohort of 400,000 hospitalised patients with Covid-19

Learn more

Accessibility and implementation of COVID-19 clinical management guidelines produced early in the COVID-19 pandemic: a global survey.

Learn more

International comparison of age-specific presenting symptoms for patients admitted to hospital with coronavirus disease 2019

Learn more

Co-infections and antimicrobial usage in hospitalised patients with COVID-19 from the ISARIC WHO CCP-UK study: a prospective, multicentre cohort study

Learn more

Evidence of lung perfusion defects and ongoing inflammation in an adolescent with Post-Acute sequelae SARS-CoV-2 infection

Learn more

What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? – a harmonised, global longitudinal observational study protocol

Learn more

COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospectve multinational observational study

The ISARIC prospective multinational observational study is the largest cohort of hospitalized patients with COVID-19. We present relationships of age, sex, and nationality to presenting symptoms. Learn more

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development

Learn more

The impact of COVID-19 on clinical research for Neglected Tropical Diseases (NTDs): a case study of bubonic plague

Among the many collaterals of the COVID-19 pandemic is the disruption of health services and vital clinical research. COVID-19 has magnified the challenges faced in research and threatens to slow research for urgently needed therapeutics for Neglected Tropical Diseases (NTDs) and diseases affecting the most vulnerable populations. Here we explore the impact of the pandemic on a clinical trial for plague therapeutics and strategies that have been considered to ensure research efforts continue. Learn more

Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort

Learn more

Setting priorities to address research gaps in Long-term COVID-19 outcomes in children

Learn more

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: A prospective, multicentre cohort study

COVID-19 is a multisystem disease and patients who survive might have in-hospital complications. These complications are likely to have important short-term and long-term consequences for patients, health-care utilisation, health-care system preparedness, and society amidst the ongoing COVID-19 pandemic. Our aim was to characterise the extent and effect of COVID-19 complications, particularly in those who survive, using the International Severe Acute Respiratory and Emerging Infections ... Learn more

Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19

The long-term sequalae of COVID-19 remain poorly characterized. We assessed persistent symptoms in previously hospitalized patients with COVID-19 and assessed potential risk factors. Learn more

Risk factors for long-term consequences of COVID-19 in hospitalised children in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study – Preprint

Learn more

Evaluating clinical characteristics studies produced early in the Covid-19 pandemic:a systematic review

Clinical characterisation studies have been essential in helping inform research, diagnosis and clinical management efforts, particularly early in a pandemic. This systematic review summarises the early literature on clinical characteristics of patients admitted to hospital, and evaluates the quality of evidence produced during the initial stages of the pandemic. Learn more

Characterising long-term covid-19: a living systematic review

Learn more

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Learn more

What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review

Learn more

Research priorities for Long Covid: refined through an international multi-stakeholder forum

Learn more

Children hospitalised with Omicron did not have a higher risk of experiencing long-term health issues compared to other infections, finds latest study

A new study finds that children hospitalised with initial COVID-19 variant showed more signs of dermatological, fatigue, gastrointestinal, sensory, and sleep issues, as well as behavioural and emotional problems

Researchers start new investigation into Long COVID core outcome set

A group of researchers started this project with the aims of understanding what are the core outcomes for patients living with Long COVID.

ISARIC COVID-19 clinical database passes the half million patient records mark

On its 10th anniversary, University of Oxford’s ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) demonstrates the crucial role of global preparedness and collaboration for advancing knowledge on infectious disease pandemics.

Activities

Non-invasive ventilation strategies in COVID-19 – sharing experiences

This forum aims to review evidence and strategies for Non-invasive ventilation (NIV) in COVID, develop and promote research ideas and evidence-based practice.

How India is identifying best practice in the use of Corticosteroids in COVID-19

ISARIC partners have been at the forefront of clinical trials of COVID-19 treatments since the start of the pandemic. Recognising how hard it is to keep up with the extraordinary pace of COVID science, ISARIC will run a series of ‘Evidence Fora’ on COVID-19 treatment.

Long COVID Forum: 9-10 December 2020

Currently very little is known about the clinical, biological, psychological and socio-environmental impact of Coronavirus Disease 2019 (COVID-19). While most people have uncomplicated recoveries, some continue to live with prolonged illness and symptoms.